Deletion mapping at 12p12-13 in metastatic prostate cancer

Genes Chromosomes and Cancer

Volumn 25, Issue 3, 1999, Pages 270-276

  Kibel, Adam S ^a,b   Freije, Diha ^a   Isaacs, William B ^a   Bova, G Steven ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CASE REPORT; CHROMOSOMAL LOCALIZATION; CHROMOSOME 12P; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME MAP; EXPRESSED SEQUENCE TAG; GENE AMPLIFICATION; HETEROZYGOSITY LOSS; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; XENOGRAFT; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; BONE NEOPLASMS; CARCINOMA; CHROMOSOME DELETION; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 12; CONTIG MAPPING; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; PROSTATIC NEOPLASMS; RIBS;

ENICOSTEMA;

EID: 0033035090     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.0.CO;2-Z     Document Type: Article

References (32)

1. Baccichet A, Sinnett D. 1997. Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia. Br J Haematol 99:107-114.
2. Bookstein R, Bova GS, MacGrogan D, Levy A, Isaacs WB. 1997. Tumour-suppressor genes in prostatic oncogenesis: a positional approach. Brit J Urol 79(suppl 1):28-36.
3. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwarra Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. 1993. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873.
4. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. 1996. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc Nat Acad Sci USA 93:14845-14850.
5. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. 1997. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3:227-230.
6. Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P. 1998. Expression of p27kipl in prostatic adenocarcinoma. Mod Pathol 11:324-328.
7. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI. 1998. Distinct patterns of p27/kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Nat Cancer Inst 90:1284-1291.
8. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. 1998. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Nat Cancer Inst 90:916-920.
9. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. 1986. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323:643-646.
10. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307-316
11. Golub TR, Barker GF, Bohlander SK. Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG. 1995. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Nat Acad Sci USA 92:4917-4921.
12. Golub TR. 1997. TEL gene rearrangements in myeloid malignancy. Hematol Oncol Clin North Am 11:1207-1220.
13. Guo Y, Sklar GN, Borkowski A, Kyprianou N. 1997. Loss of the cyclin-dependent kinase inhibitor p27Kip1 protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3:2269-2274.
14. Kawamata N, Morosetti R, Miller CW, Park D. Spinn KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S, Lee YY, Bartram CR, Koeffler HP. 1995. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 55:2266-2269.
15. Kibel AS, Schutte M, Kern SE, Isaacs WB, Bova GS. 1998. Identification of 12p as a region of frequent deletion in advanced prostate cancer. Cancer Res 58:5652-5655.
16. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. 1998. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184-187.
17. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
18. Loda M, Cukor B, Tam SW. Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.
19. Marshall CT. 1991. Tumor suppressor genes. Cell 64:313-326.
20. Morton RA, Ewing CM, Nagafuchi A, Tsukita S, Isaacs WB. 1993. Reduction of E-cadherin levels, and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 53:3585-3590.
21. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. 1995. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 55:34-38
22. Paul R, Ewing CM, Jarrard DF, Isaacs WB. 1997. The cadherin cell-cell adhesion pathway in prostate cancer progression. Brit J Urol 79(suppl 1):37-43.
23. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J. 1994. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66.
24. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K. Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C. 1995. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211-1214.
25. Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. 1991. Allelotype of human ovarian cancer. Cancer Res 51:5118-5122.
26. Schutte M, da Costa LT, Hahn SA, Moskaluk C, Hoque AT, Rozenblum E, Weinstein CL, Bittner M, Meltzer PS, Trent JM, Yeo CJ, Hruban RH, Kern SE. 1995. Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Nat Acad Sci USA 92:5950-5954.
27. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB, Bova GS. 1998. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 58:204-209.
28. Takeuchi S, Mori N, Koike M, Slater J, Park S. Miller CW, Miyoshi I, Koeffler HP. 1996. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res 56:738-740.
29. Toyoshima H, Hunter T. 1994. p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78:67-74.
30. Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. 1998. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 58:542-548.
31. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M, Reiter RE. 1998. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159:941-945.
32. Yatabe Y, Masuda A, Koshikawa T, Nakamura S, Kuroishi T, Osada H, Takahashi T, Mitsudomi T, Takahashi T. 1998. p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res 58:1042-1047.